Plasma Exchange Reduces Cancer Therapy Resistance by Removing Soluble Proteins
Therapeutic plasma exchange successfully reduced soluble mesothelin levels by 44%, potentially restoring cancer drug effectiveness.
Summary
Researchers found that soluble mesothelin (sMSLN) interferes with cancer treatments by binding to therapeutic antibodies before they reach tumor cells. Therapeutic plasma exchange (TPE) consistently reduced sMSLN levels by an average of 44% in 15 patients. This procedure could potentially restore the effectiveness of mesothelin-targeted cancer therapies, which are being developed for mesothelioma, lung cancer, and other malignancies. The study suggests TPE may be more reliable than protease inhibitors for reducing problematic soluble proteins that cause treatment resistance.
Detailed Summary
Cancer cells often shed pieces of their surface proteins into the bloodstream, creating soluble versions that can interfere with targeted therapies. This study investigated whether therapeutic plasma exchange (TPE) could reduce these problematic proteins and restore treatment effectiveness.
Researchers focused on soluble mesothelin (sMSLN), a protein shed from cancer cells that appears to neutralize mesothelin-targeted therapies. They studied 15 patients undergoing routine TPE for various medical conditions, measuring sMSLN levels before and after the procedure. They also tested whether protease inhibitors could prevent protein shedding and improve drug effectiveness.
TPE consistently reduced sMSLN levels by an average of 44% (15.4 ng/mL) across all patients, regardless of their cancer history. Laboratory experiments confirmed that sMSLN binds to and sequesters the cancer drug anetumab, reducing its ability to kill cancer cells. When researchers added recombinant mesothelin (mimicking high sMSLN levels) to cell cultures, it significantly reduced the cytotoxic effects of anetumab ravtansine, an antibody-drug conjugate.
Protease inhibitors showed mixed results in stabilizing surface mesothelin and improving drug effectiveness. The combination of marimastat and TMI-1 actually reduced cell viability on its own, complicating interpretation of results. This suggests TPE may be more reliable than protease inhibitors for clinical applications.
These findings have broader implications beyond mesothelin, as many cancer therapies face similar resistance from soluble proteins like PD-L1, LAG3, and BCMA. TPE could potentially enhance the effectiveness of various targeted cancer treatments by removing these interfering proteins from circulation.
Key Findings
- Therapeutic plasma exchange reduced soluble mesothelin levels by 44% in all patients
- Soluble mesothelin binds to and neutralizes mesothelin-targeted cancer drugs
- Higher soluble protein levels correlated with reduced drug cytotoxicity in lab tests
- TPE showed more consistent results than protease inhibitors for protein reduction
- Approach may apply to other soluble proteins causing cancer treatment resistance
Methodology
Study analyzed matched pre- and post-TPE plasma samples from 15 patients using ELISA assays. Cell culture experiments tested cytotoxicity of anetumab ravtansine with and without recombinant mesothelin and protease inhibitors.
Study Limitations
Small patient sample size and diverse underlying conditions. Cell culture experiments used recombinant protein rather than actual patient-derived soluble mesothelin. Long-term effects and optimal timing of TPE relative to cancer treatment remain unclear.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.